Cellworks and ISP Personal Care Collaborate to Demonstrate Proteomics-Based Computer Modeling of Skin Biology
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
Cellworks Group Inc. and ISP Personal Care have announced that they have formed an alliance to use sophisticated computer modeling techniques to develop and demonstrate novel skin care approaches based on ISP’s Vincience line of biofunctional ingredients.
In a recently concluded study, Cellworks Group’s Virtual Skin platform was used to model the effects in two biofunctional ingredient projects that were under evaluation for effects on skin pigmentation.
The study was able to assay hundreds of bio-molecules, examining different application rates and allowing ISP to predict their effects on different skin types – before the need for expensive clinical testing. Laboratory work by ISP was able to validate the accuracy of the results produced via Cellworks Group’s Virtual Skin platform.
This study was the first in a series of collaborations between the two companies that will also include work on anti-aging compounds and synergies between different biofunctional ingredients. The alliance is an outgrowth of ISP Personal Care’s recently announced Avant Institute for developing scientific and commercial innovation for the personal care industry.
According to Dr. Claude Dal Farra, Vice President of Research & Development for ISP, Cellworks Group’s Virtual Cells technology has the potential to dramatically speed up the discovery and development of biofunctional ingredients, to improve the targeting and efficacy of those ingredients, and to deliver important data to skin care companies for use in their own product development processes.
“The ability of the Cellworks Group’s Virtual Skin platform to perform complex experiments with easy setup and to analyze hundreds of bio-molecules and skin attributes gives us unprecedented insight into the workings of biofunctionals we have under development,” he said.
“We've been closely working with the Cellworks Group to validate the predictive power of their technology and were very impressed with the accuracy of their system and the ease of interacting with the technology. Working with their virtual skin platform in order to model the interaction of the melanocyte, keratinocyte and fibroblast is a tremendous advantage as the co-culture equivalent would require primary cell lines that only last 48 hours at best, imposing high costs and extreme time pressures. This technology has the ability to improve the productivity of our scientists and enable us to get better products to market in a shorter time,” he added.
In a recently concluded study, Cellworks Group’s Virtual Skin platform was used to model the effects in two biofunctional ingredient projects that were under evaluation for effects on skin pigmentation.
The study was able to assay hundreds of bio-molecules, examining different application rates and allowing ISP to predict their effects on different skin types – before the need for expensive clinical testing. Laboratory work by ISP was able to validate the accuracy of the results produced via Cellworks Group’s Virtual Skin platform.
This study was the first in a series of collaborations between the two companies that will also include work on anti-aging compounds and synergies between different biofunctional ingredients. The alliance is an outgrowth of ISP Personal Care’s recently announced Avant Institute for developing scientific and commercial innovation for the personal care industry.
According to Dr. Claude Dal Farra, Vice President of Research & Development for ISP, Cellworks Group’s Virtual Cells technology has the potential to dramatically speed up the discovery and development of biofunctional ingredients, to improve the targeting and efficacy of those ingredients, and to deliver important data to skin care companies for use in their own product development processes.
“The ability of the Cellworks Group’s Virtual Skin platform to perform complex experiments with easy setup and to analyze hundreds of bio-molecules and skin attributes gives us unprecedented insight into the workings of biofunctionals we have under development,” he said.
“We've been closely working with the Cellworks Group to validate the predictive power of their technology and were very impressed with the accuracy of their system and the ease of interacting with the technology. Working with their virtual skin platform in order to model the interaction of the melanocyte, keratinocyte and fibroblast is a tremendous advantage as the co-culture equivalent would require primary cell lines that only last 48 hours at best, imposing high costs and extreme time pressures. This technology has the ability to improve the productivity of our scientists and enable us to get better products to market in a shorter time,” he added.
